| Title |
RGD-K5 PET/CT in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy: Results from a pilot study
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, February 2016
|
| DOI | 10.1007/s00259-016-3345-1 |
| Pubmed ID | |
| Authors | |
| Abstract |
We prospectively investigated the potential usefulness of PET using a new tracer targeting integrin αvβ3 (termed RGD-K5) in patients with head and neck cancer (HNC) undergoing definitive concurrent chemoradiotherapy (CCRT). Newly diagnosed patients with locally advanced HNC scheduled for definitive CCRT were eligible. RDG-K5 PET and FDG PET scans were performed at three different time points (baseline, 2 weeks, and 3 months post-treatment). Nine patients completed all of the three scans, whereas two patients withdrew after two scans only. Uptake of both RGD-K5 and FDG generally decreased following CCRT. However, the observed decrease did not differ significantly between complete responders and non-responders. At 3 months post-treatment, the uptake of both RGD-K5 and FDG at the main tumors was significantly lower in those who achieved complete responses than in those with residual tumors. RGD-K5 PET has the potential to identify patients with incomplete responses to CCRT. |
Login to access the Attention Digest and the Sentiment Analysis related to this output.
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 15 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 5 | 33% |
| Student > Ph. D. Student | 3 | 20% |
| Student > Doctoral Student | 1 | 7% |
| Student > Master | 1 | 7% |
| Researcher | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 4 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 47% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Psychology | 1 | 7% |
| Neuroscience | 1 | 7% |
| Other | 0 | 0% |
| Unknown | 4 | 27% |